pharmaphorum

FEBRUARY 3, 2021

However, caveats surrounding the stochastic off-target outcomes of cleaving both strands of the DNA helix to elicit a gene modification remain a source of concern. Traditional CRISPR-Cas9 technology relies on generating a DSB in the DNA to facilitate a genetic modification. Base editing to get cell therapies on point.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

FEBRUARY 21, 2022

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production.

Marketing 52

Marketing Gene Sequencing DNA Genomics 52

The Pharma Data

AUGUST 19, 2021

The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. 4,5,6 PD-1 inhibitors can be effective in cancers with MMR deficiency.

FDA Approval 52

FDA Approval DNA Reagent Protein 52

The Pharma Data

MARCH 20, 2021

The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. delays where reagents are in. DNA biomarker services in an accredited environment. significant miniaturization and reduction in reagent. The MANTIS.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Roots Analysis

FEBRUARY 23, 2022

Further, NGS library preparation kits offer several benefits, such as low requirement of starting material, generation of longer RNA / DNA sequences and production of superior quality nucleotide libraries, thereby, catering to existing unmet needs of the research domain. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

JANUARY 31, 2021

Illumina , the world’s leading DNA sequencing and array-based technologies company, is partnering with Sequoia Capital China, an investment firm, to launch a life sciences incubator in China. It is dubbed the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Life Science 52

Life Science Genome Genomics Reagent 52

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. Elsewhere around the globe: RevoluGen – U.K.-based

Drugs 52

Drugs Gene Editing Genomics Genome 52

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution.

Genome 52

Genome Genomics RNA Genome Project 52

The Pharma Data

JANUARY 31, 2021

NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina. .”

Genome 52

Genome Genomics Life Science DNA 52

Roots Analysis

AUGUST 15, 2023

Further, other improvements, including efficient production cycles, use of low-cost reagents and development of purified component platforms, have made cell free biomanufacturing a preferred option for synthesis of various types of biologics and small molecules.

Protein 52

Protein In-Vitro Reagent Production 52

pharmaphorum

JUNE 1, 2021

Two different types of microtaggants are now available, one produced from non-biologic DNA and the other from silica: DNA microtaggants. DNA is robust and easy to detect and because it is possible to produce different versions of the same DNA molecule, it can be made regional, product, or company-specific.

Medicine 52

Medicine DNA Pharmacy Production 52

The Pharma Data

JULY 11, 2021

TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

XTalks

OCTOBER 1, 2020

At Nurix, Dr. Hansen focuses on establishing the company’s DNA-encoded library technology platform for small molecule identification and leading the discovery organization. Hansen says she has a good appreciation of what would be essential for good collaboration projects that academics could be engaged for.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

OCTOBER 14, 2020

Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

AUGUST 4, 2020

Accurate monitoring of Epstein-Barr virus DNA levels is critical, as they are associated with a range of life threatening-diseases including cancer in transplant patients. This is the first quantitative in vitro diagnostic test for Epstein-Barr virus (EBV) DNA in the United States. For more information, please visit www.roche.com.

DNA 52

DNA In-Vitro Medicine Reagent 52

The Pharma Data

SEPTEMBER 7, 2020

to obtain comparable results when measuring levels of BKV DNA. The test offers an alternative to lab-developed tests (LDTs) or Analyte Specific Reagent (ASR) combinations, potentially minimising variability and complexity in testing, reducing workload and alleviating risk for laboratories. IU/mL and an expanded linear range from 21.5

In-Vitro 52

In-Vitro Medicine Reagent DNA 52